SOLICITATION NOTICE
B -- Microsatellite Instability Coding and Analysis of Endometrial and Ovarian Cancers in the Polish Endometrial and Ovarian Cancer Case-Control Study, and the SEER Residual Tissue Repository study
- Notice Date
- 8/19/2009
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90195-KM
- Archive Date
- 9/18/2009
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB), plans to enter into a sole source procurement for Microsatellite Instability Coding and Analysis of Endometrial and Ovarian Cancers in the Polish Endometrial and Ovarian Cancer Case-Control Study, and the SEER Residual Tissue Repository study, with Deutsches Krebsforschungszentrum (DKFZ), German Cancer Research Center, Technologietransfer; Im Neuenheimer Feld 280; D-69120 Heidelberg, Germany. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System Code is 541711 and the business size standard is 500 employees. The period of performance shall be twelve (12) months from date of award. DNA mismatch repair deficiency is related to mutations or methylation of mismatch repair genes and causes various sporadic and hereditary cancers (e.g. the hereditary non-polyposis colorectal cancer syndrome, HNPCC). The loss of DNA mismatch repair capability leads to accumulation of DNA errors in cells and to the generation of malignant cell clones. Mismatch repair deficiency is cancer-initiating and results in distinct pathologic and clinical features. Mismatch repair deficiency can be identified by loss of DNA mismatch repair protein expression in immunohistochemistry and by detecting length variations in repetitive DNA sequences (microsatellite instability). Hospital–based studies have reported MSI frequencies of up to 20% in endometrial cancers and up to 12% in ovarian cancers (mainly related to sporadic mutations of mismatch repair genes). The purpose of this requirement is to analyze microsatellite instability as an indicator of mismatch repair deficiency in endometrial and ovarian cancer cases derived from two DCEG-based studies. The Polish Endometrial and Ovarian Case-Control Study is a case-control study that includes population-based incident cases, excellent risk factor data, detailed histology information, and survival data. The SEER ovarian cancer Residual Tissue Repository (RTR) study has collected population-based data and tissues of epithelial ovarian cancer cases from three SEER repositories. For these cases, detailed histology information, age, race, and survival data is available. The researchers at the German Cancer Research Center have developed a novel MSI testing assay using a marker panel that does not require the analysis of normal tissue in parallel, including the marker CAT25 newly identified by this group. Used as a single marker, CAT25 has a higher sensitivity and specificity for the detection of mismatch repair deficiency than any other MSI marker published so far. The MSI testing assay (CAT25 combined with additional markers BAT25 and BAT26) has been validated in colorectal cancers and endometrial cancers, showing a performance identical to the standard Bethesda marker panel, but without the need to analyze normal tissue. The MSI testing assay offered by the group represents the most accurate currently available system for MSI analysis and does not require concomitant analysis of normal tissue. In addition to the MSI testing assay, the group has developed a unique bioinformatics-based tool that allows predicting the functional relevance of defined coding microsatellite mutations to tumor development. Based on this bioinformatics model, the group has established mutation analysis for an extensive panel of coding microsatellite markers that allow studying the carcinogenic pathways involved in MSI-related carcinogenesis in detail. Currently, there is no other provider that offers reliable MSI testing from tumor tissue alone and that offers a large panel of coding microsatellites to analyze MSI-positive cancers. In addition, since only tumor tissue for every case is analyzed, MSI testing is less costly than IHC or conventional MSI analysis. This is not a solicitation for competitive quotations. However, if any interested party believes it can perform the requirement as detailed they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient details to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the contracting office on or before 11:00 am ET, on September 3, 2009. All questions must be in writing and must be emailed to Karri Mares, maresk@mail.nih.gov or faxed to (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI, contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov In addition; contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. Please reference NCI-90195-KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90195-KM/listing.html)
- Record
- SN01918247-W 20090821/090820001106-a9360dbbd6f2d15a2476228c9d70d68b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |